Auto Amazon Links: No products found.
In the UK, the initial volunteers have recently received an experimental vaccine designed to guard against a possible bird flu pandemic. This vaccine specifically targets the H5N1 strain, which has devastated bird populations globally and has also been detected in some mammal species. According to the UK Health Protection Agency, the current risk to humans remains low, with the majority of human infections traced back to direct contact with infected animals.
The new vaccine employs mRNA technology, similar to that used in the Covid-19 immunizations, allowing for rapid and large-scale production should a pandemic arise. The ongoing trial aims to enlist individuals most vulnerable to the virus, particularly those employed in the poultry sector and people over 65 years old. One of the first to receive the vaccine was Clare Howard from Hampshire, an experienced chicken keeper, who described the process as straightforward and potentially very important.
This extensive trial plans to involve 4,000 participants, with three-quarters recruited across 26 sites in England and Scotland, and the remainder based in the United States. Dr. Rebecca Clark, the national coordinating investigator, highlighted that the H5N1 strain is continuously evolving and spreading among animal hosts. She stressed the importance of preparing for the possibility of human-to-human transmission, stating, “This trial is our proactive attempt to shield against that possibility, and any future pandemic that could emerge from it.”
The study’s purpose is to assess the vaccine’s safety and its ability to provoke a strong immune response. If successful, the vaccine could be authorized for wider use. Professor Lucy Chappell, chief scientific adviser at the Department of Health and Social Care and CEO of the National Institute for Health and Care Research, emphasized that the trial strengthens the nation’s pandemic preparedness. Production of the vaccine would take place at Moderna’s Harwell facility in Oxfordshire, which currently manufactures Covid vaccines and has the capacity to scale up from 100 million to 250 million doses annually during a pandemic scenario
Read the full article from The BBC here: Read More
Auto Amazon Links: No products found.